Tempus vs Insilico Medicine — Comparison

Tempus

Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, startin

Christina Antoniou Senior Vice President, Head of Corporate Development Terron Bruner Chief Commercial Officer Ezra Cohen, MD Chief Medical Officer of Oncology Shane Colley Chief Technology Officer Robyn Eckerling Chief Privacy Officer Laura Elster Senior Vice President, Healthcare Innovation & Transformation Greg Fisbeck Chief Information Security Officer Ryan Fukushima Chief Operating Officer Stacey Kraft Chief People Officer Andy Moye, PhD SVP & GM, Data Products Halla Nimeiri, MD Chief Development Officer Phil Perez Senior Vice President, Commercial Life Sciences Erik Phelps EVP and Chief Administrative and Legal Officer Jim Rogers Chief Financial Officer Kate Sasser, PhD Chief Scientific Officer Tom Schoenherr CEO, Ambry Genetics Chris Scotto DiVetta Senior Vice President & General Manager of AI Applications Lauren Silvis Senior Vice President of External Affairs Patty Spiller Chief Marketing Officer Melisa Tucker Chief Data Officer Shane Woods, PhD Chief Strategy Officer Mike Yasiejko Executive Vice President and General Manager, Genomics “We are thrilled to have led an investment in Tempus... Given NEA's long and successful history investing in the intersection of technology and life science, we felt like the perfect strategic partner given Tempus' mission to help doctors personalize care by collecting and analyzing large volumes of data.” Peter Barris, Chairman & General Partner, New Enterprise Associates “The next major evolution in health care will be the embrace of data to dramatically improve patient outcomes, and I believe Tempus is the company that is best positioned to lead this transition. The team at Tempus is exceptional, and as committed to the mission as can be.” Eric Belcher, Chief Executive Officer, Numerator “I look forward to working with the Tempus team as they continue to apply technology and artificial intelligence to healthcare, deploying intelligent diagnostics that enhance research, empower physicians, and positively change the lives of patients.” Jennifer Doudna, PhD, Li Ka Shing Chancellor’s Professor of Biomedical Science, University of California, Berkeley and Founder, Innovative Genomics Institute “Tempus has developed a distinct set of solutions that has real potential to revolutionize cancer care. I look forward to working with the leadership team in developing those offerings to provide even more value to the company, its partners, and ultimately patients.” David R. Epstein, Former Chief Executive Officer, Seagen “As a surgical oncologist, I have worked to reduce racial, ethnic and gender health care disparities throughout my career. Tempus is a leader in the field of data-driven medicine, and I am excited to work with their team to further enhance patient outcomes for individuals of all backgrounds and from all communities.” Wayne A. I. Frederick, MD, MBA, Charles R. Drew Professor of Surgery “I'm honored to be working with the Tempus team as they advance innovative tools for

Insilico Medicine

Generative AI and Automation for Longevity and Sustainability

I notice that the reviews section is empty and the social mentions only show YouTube titles repeating "Insilico Medicine AI" without any actual review content or user feedback. Without substantive user reviews, comments, or detailed social media discussions, I cannot provide a meaningful summary of what users think about Insilico Medicine's strengths, weaknesses, pricing, or overall reputation. To generate an accurate user sentiment analysis, I would need access to the actual content of reviews, comments, or more detailed social media posts about their AI drug discovery platform.

Tempus

Insilico Medicine

Tempus

Insilico Medicine

Tempus

Insilico Medicine